Exfoliation Syndrome, Ocular Hypertension, Open Angle Glaucoma
Conditions
Brief summary
Glaucoma is the world's the second leading cause of irreversible blindness. The World Health Organization (WHO) estimated the incidence of blindness due to glaucoma to be 4.4 million people worldwide in 2002. Intraocular pressure (IOP) is the sole proven modifiable risk factor for the development and progression of glaucomatous optic neuropathy. Medical therapy is aimed at lowering IOP in order to prevent or slow progression. Exfoliation syndrome (XFS) is the most common identifiable cause of open-angle glaucoma, affecting an estimated 60 to 70 million people worldwide. Approximately two-thirds of patients have disease in only one eye on clinical examination; however, XFS is detectable in the other eye with conjunctival biopsy. XFS is also a systemic disease, with effects on the cardiovascular and cerebrovascular systems. Patients with XFS are twice as likely to convert from ocular hypertension to glaucoma. Glaucoma in XFS is more severe than primary open angle glaucoma. There is greater diurnal IOP fluctuation, greater visual field loss and optic nerve head damage at the time of diagnosis, poorer response to medications, more rapid visual field progression and more frequent need for surgery. Because you meet eligibility criteria for our study, we ask for your consent to participate in the study described below. In brief, you will be taking an investigational drug (AR-12286, rho-kinase Inhibitor) at either 0.5% or 0.7% once a day for 6 months. This drug is currently being tested in patients with primary open-angle glaucoma, but not yet in glaucoma in exfoliation syndrome. Because of the mechanism of glaucoma in XFS and the mechanism of action of rho-kinase inhibitors, there is reason to think it would be more effective in eyes with XFS and glaucoma than in primary open-angle glaucoma (ordinary glaucoma). There will be a baseline and study day 1 visit, week 1 visit, month 1 and 3 visit, week 13 visit, month 6 visit and a week 25 visit; for a total of 7 office visits.
Interventions
DRUGAR-12286
Sponsors
Robert Ritch, MD, LLC.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
50 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* 50-85 y.o. * Male and Female * Exfoliation Syndrome and ocular hypertension or mild or moderate exfoliative glaucoma * IOP ≥22 mmHg prior to initiation of treatment in one or both eyes with two measurements taken two hours apart * No previous intraocular surgery except clear cornea phacoemulsification * Corrected visual acuity in both eyes ≥20/50 in the eligible eye * Not more than 6 diopters spherical equivalent on the study eye * Not more than 3 diopters cylinder equivalent on the study eye * Have given written informed consent, prior to any investigational procedures * Ability to attend for the 6-month duration of the study
Exclusion criteria
* Open angle glaucoma other than exfoliative glaucoma * Closed angle glaucoma (primary or secondary) * Intraocular pressure \>30 mm Hg * Severe exfoliation glaucoma * Known hypersensitivity to any component of the formulation (benzalkonium chloride, etc.), or to topical anesthetics * Previous intraocular surgery except clear cornea phacoemulsification * Clinically significant ocular disease (e.g. corneal edema, uveitis, severe keratoconjunctivitis sicca) which might interfere with the study * Ocular medication of any kind within 30 days of base-line visit, with the exception of ocular hypotensive medications and/or lubricating drops for dry eye (which may be used throughout the study) * Any abnormality preventing reliable applanation tonometry of either eye * Clinically significant systemic disease (e.g., uncontrolled diabetes, myasthenia gravis, hepatic, renal, endocrine or cardiovascular disorders) which might interfere with the study * Changes of systemic medication that could have a substantial effect on IOP anticipated during the study * Participation in any investigational study within the past 30 days * Inability to perform reliable VF testing * Unwilling to sign the consent form approved by the Institutional Review Board (IRB) of the New York Eye and Ear Infirmary * Self-reported poor compliance to treatment * Reluctance to return for scheduled follow-up visits * Patients not able to understand the nature of the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Evaluate the Ocular Hypotensive Efficacy of Rho Kinase Inhibitor (AR-12286 0.5% and 0.7%) | 6 months | Goldmann Aplanation Tonometry (IOP mmHg) will be used to measure the ocular hypotensive efficacy. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| 0.5% 0.5% Rho-Kinase Inhibitor
AR-12286 | 5 |
| 0.7% 0.7% Rho-Kinase Inhibitor
AR-12286 | 5 |
| Total | 10 |
Baseline characteristics
| Characteristic | 0.5% | 0.7% | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 3 Participants | 5 Participants | 8 Participants |
| Age, Categorical Between 18 and 65 years | 2 Participants | 0 Participants | 2 Participants |
| Sex: Female, Male Female | 2 Participants | 2 Participants | 4 Participants |
| Sex: Female, Male Male | 3 Participants | 3 Participants | 6 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 1 / 5 | 0 / 5 |
| serious Total, serious adverse events | 0 / 5 | 0 / 5 |
Outcome results
Primary
Evaluate the Ocular Hypotensive Efficacy of Rho Kinase Inhibitor (AR-12286 0.5% and 0.7%)
Goldmann Aplanation Tonometry (IOP mmHg) will be used to measure the ocular hypotensive efficacy.
Time frame: 6 months
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| 0.5% | Evaluate the Ocular Hypotensive Efficacy of Rho Kinase Inhibitor (AR-12286 0.5% and 0.7%) | 24.2 mmHg | Standard Deviation 2.4 |
| 0.7% | Evaluate the Ocular Hypotensive Efficacy of Rho Kinase Inhibitor (AR-12286 0.5% and 0.7%) | 25.8 mmHg | Standard Deviation 2.4 |